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Background/aim: Irisin, a newly identified exercise-derived myokine, has been found involved in a peripheral vasodilator effect. However,
little is known regarding the potential vascular activity of irisin, and the mechanisms underlying its effects on vascular smooth muscle have
not been fully elucidated. This study was aimed to investigate the effects of irisin on vascular smooth muscle contractility in rat thoracic
aorta, and the hypothesis that protein kinase C (PKC) may have a role in these effects.
Materials and methods: Isometric contraction-relaxation responses of thoracic aorta rings were measured with an isolated organ bath
model. The steady contraction was induced with 10 µM phenylephrine (PHE), and then the concentration-dependent responses of irisin
(0.001-1 µM) were examined. The time-matched vehicle control (double distilled water) group was also formed. To evaluate the role of PKC,
endothelium-intact thoracic aorta rings were incubated with 150 nM bisindolylmaleimide I (BIM I) for 20 min before the addition of 10 µM
PHE and irisin. Also, a vehicle control group was formed for dimethyl sulfoxide (DMSO).
Results: Irisin exerted the vasorelaxant effects at concentrations of 0.01, 0.1, and 1 µM compared to the control group (p < 0.001). Besides,
PKC inhibitor BIM I incubation significantly inhibited the relaxation responses induced by varying concentrations of irisin (p: 0.000 for 0.01
µM; p: 0.000 for 0.1 µM; p: 0.000 for 1 µM). However, DMSO, a solvent of BIM I, did not modulate the relaxant effects of irisin (p > 0.05).
Conclusion: In conclusion, physiological findings were obtained regarding the functional relaxing effects of irisin in rat thoracic aorta. The
findings demonstrated that irisin induces relaxation responses in endothelium-intact thoracic aorta rings in a concentration-dependent
manner. Furthermore, this study is the first to report that irisin-induced relaxation responses are regulated probably via activating signaling
pathways implicating PKC.
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1. Introduction
Irisin, a newly identified hormone-containing 112 amino
acids, which is secreted mainly by skeletal muscle cells
during exercise, is a cleavage product of fibronectin type
III domain-containing protein 5 (FNDC5) [1]. Irisin
increases mitochondrial biogenesis and energy expenditure
by activating the conversion of white adipocytes to brown
adipocytes [1,2]. Circulating levels of irisin are associated
with obesity, type II diabetes mellitus, insulin resistance,
hypertension, and atherosclerosis. Recently, one of the
agents predicted to be used in the prevention, follow-up, and
treatment of these metabolic diseases and/or pathologies is
the irisin molecule [3-5].
Vasoreactivity is of fundamental importance in various
cardiovascular diseases such as hypertension, headache,
and stroke [6]. Although some studies have demonstrated
the peripheral vasodilator effect of irisin, little is known
about the potential vascular activity of this molecule,

and the mechanisms underlying its effects on vascular
smooth muscle contraction-relaxation responses have not
been fully elucidated yet. Besides, studies with this newly
discovered adipomyokine have had several conflicting
results. Therefore, more studies are needed to demonstrate
the functional effects of irisin on vascular tissue and the
mechanisms involved in these effects.
In the present study, it was aimed to investigate the
effects of irisin on vascular smooth muscle contractility on
rat thoracic aorta, a conducting artery, and the possible roles
of protein kinase C (PKC) and dimethyl sulfoxide (DMSO),
a solvent of PKC inhibitor bisindolylmaleimide I (BIM I).
2. Materials and methods
2.1. Ethics
This study was approved by the decision of Bursa Uludağ
University Animal Experiments Local Ethics Committee
dated 03/04/2019 and numbered 2019-04/10.
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2.2. Test animals
In this study, male Wistar Albino rats (10-12 weeks of age),
obtained from Bursa Uludağ University Experimental
Animals Breeding Application and Research Center, were
used. All experiments were performed according to the
National Institutes of Health Guidelines on the Use of
Laboratory Animals.
2.3. Chemicals and reagents used in experiments
Irisin, BIM I, phenylephrine hydrochloride (PHE),
acetylcholine chloride (ACh), DMSO, and chemicals
required to prepare Krebs solution used in the experiments
were purchased from Sigma Aldrich (St Louis, MO, USA).
Irisin, PHE, and ACh were dissolved in distilled water;
BIM I was dissolved in DMSO.
2.4. Isolated organ bath experiments
2.4.1. Preparation of aortic rings and mounting in organ
baths
The animals used in the experiments were decapitated
without anesthesia, taking care that they were not exposed
to any stress factors. The thoracic cavity of the animals
was opened rapidly and then the thoracic aorta was gently
removed and placed in a Petri dish containing 0-4 °C Krebs
solution. The Krebs solution contained: NaCl 119.0 mM,
KCl 4.7 mM, MgSO4 1.5 mM, KH2PO4 1.2 mM, CaCl2
2.5 mM, NaHCO3 25.0 mM, and glucose 11.0 mM. The
isolated vessels were cleared of adhering fat and connective
tissue and then divided into 2-3 mm rings. Thoracic aorta
rings were connected to the isometric force transducer
(SS12LA force transducer, BIOPAC Systems, Inc. Aero
Camino, USA) of the four-chamber organ bath (Commat
Ltd., Ankara, Turkey) through steel wires as rapidly as
possible to measure the isometric contractile responses.
The temperature of the organ bath was kept constant at
37 °C (±0.5 °C) through a thermocirculator containing
distilled water. The organ bath chambers were oxygenated
with 95% O2-5% CO2 mixed gas during the experiment to
maintain a pH of 7.4. Briefly, the isolated organ bath model
was used as previously described [7].
2.4.2. Vessel viability testing
Before each experiment, aortic rings were loaded with 2
g of resting tension and then stabilized for 60 min. The
Krebs solution, containing the tissues, was refreshed every
15 min during the equilibration period. After this period,
vessel viability and endothelial integrity were estimated
by its stable and reproducible response to the addition of
10-5 M PHE and 10-5 M ACh. Those with >60% relaxation
against ACh among the vascular segments were accepted
as endothelium intact. Then, active, inhibitor, and vehicle
substance applications were precisely performed into
Krebs solution using an adjustable automatic pipette.
2.4.3. Preliminary experiments
First, in preliminary experiments, PHE was added
to isolated organ bath chambers in cumulative

concentrations (0.0001-100 µM) after the equilibration
period to determine the submaximal contraction dose.
In preliminary experiments, it was also investigated that
whether irisin, BIM I, and DMSO at the concentrations
used in the study have significant effects on basal tone on
rat thoracic aorta rings.
2.4.4. Measurements of vascular reactivity in isolated
thoracic aortas
Cumulative concentrations (0.001-1 µM) of irisin
were used in all experimental groups. 10-5 M PHE was
administrated to induce a steady contraction in the aortic
rings, and then the concentration-dependent responses of
irisin were examined to determine the vasodilative effect
of irisin on the endothelium-intact thoracic aorta (control
group). The time-matched vehicle control (double distilled
water) group was also formed.
To evaluate the role of PKC, endothelium-intact
thoracic aorta rings were incubated with 150 nM BIM I
(PKC inhibitor) for 20 min before the addition of 10 µM
PHE and irisin.
Following the incubation of inhibitor used for
mechanism research, the responses developed depending
on cumulative concentrations of irisin were compared
with the control group, and then the differences between
the relaxation amplitudes were calculated. Also, a “vehicle”
control group was formed for DMSO, which was used as
a solvent.
Eight aortic preparations were used for each of the
experimental groups formed according to the active,
inhibitor, or vehicle agents used in the study.
Contraction-relaxation responses were measured
isometrically by force transducer on the MP36 recording
system (BIOPAC Systems, Inc. Aero Camino, USA).
The records obtained were evaluated in a computer
environment with Biopac Student Lab 3.7.7 program
(BIOPAC Systems, Inc. Aero Camino, USA).
2.5. Statistical analysis
The size of the difference between the groups was calculated
by using Cohen’s d statistics for the comparison of the
independent means and the effect size was determined
as 0.30. While the power of the study was 0.80 and the
alpha value was 0.05, the minimum sample size required
was estimated at n = 5 per group. Power analysis was
done under GPower 3.1. SPSS v.23.0 program (SPSS Inc.,
Chicago, IL, USA) was used for statistical analysis. Test
of normality was determined by Shapiro Wilk test. The
data were expressed as ‘Mean ± SD (Standard Deviation)’
for parametric data. The statistical significance between
the two independent groups was analyzed using the
independent sample t-test. One-way ANOVA was used for
multiple comparisons. Dunnett’s T3 post hoc test was used
to determine the differences between groups. For groups
without the assumption of normality, Mann-Whitney U
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and Kruskal-Wallis with Dunn’s post-hoc test were used.
P values of < 0.05 were considered statistically significant.
3. Results
In preliminary experiments, the submaximal contraction
response was taken against 10 µM PHE. In all subsequent
experiments, precontractions were induced with
the addition of 10 µM PHE. Stable and reproducible
contraction responses occurred in rat thoracic aorta rings
with the submaximal concentration of PHE. In preliminary
experiments, it was also determined that irisin, BIM I, and
DMSO at the concentrations used in the study had no
significant effects on basal tone in rat thoracic aorta rings.
3.1. Irisin induced vasodilation in rat thoracic aortas
Cumulatively applied irisin induced concentrationdependent relaxation responses on endothelium-intact
rat thoracic aorta rings precontracted with PHE. The
relaxing effect of irisin was found to be significantly higher
at concentrations of 0.01, 0.1, and 1 µM compared to the
control group (double distilled water-treated rat thoracic
aorta rings) (p: 0.589 for 0.001 µM; p: 0.014 for 0.01 µM; p:
0.000 for 0.1 µM; p: 0.000 for 1 µM) (Figure 1).
3.2. PKC was involved in the irisin-induced relaxation of
rat thoracic aortas
Incubation of tissues with PKC inhibitor BIM I (150 nM)
for 20 min caused a significant change in the relaxation

responses to irisin. BIM I incubation resulted in a
statistically significant decrease in the relaxation responses
of irisin applied at cumulative concentrations of 0.01, 0.1,
and 1 µM (p: 0.039 for 0.01 µM; p: 0.000 for 0.1 µM; p:
0.000 for 1 µM). BIM I almost completely inhibited
relaxation responses to irisin (Figure 2).
3.3. DMSO did not modulate the irisin-induced
vasorelaxation effects
Incubation of tissues with DMSO (50 µL) for 10 min did
not cause a significant change in the relaxation responses
to irisin. DMSO incubation at solvent concentration did
not cause a remarkable change on any of the relaxation
responses of irisin applied at cumulative concentrations of
0.01, 0.1, and 1 µM (p: 1.000 for 0.01 µM; p: 1.000 for 0.1
µM; p: 1.000 for 1 µM). DMSO did not significantly affect
the relaxation responses to irisin (Figure 3) (Table).
4. Discussion
The aim of the present study was to investigate the
functional relaxant effects of irisin on rat thoracic aorta
and its underlying mechanisms. We have shown that
irisin can significantly induce concentration-dependent
relaxations in endothelium-intact rat thoracic aorta and
the vasorelaxant effects of irisin were associated with
PKC. The results suggest that irisin-induced relaxation
responses are regulated probably via activating signaling
pathways implicating PKC.
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Figure 1. Concentration-dependent relaxant effects of irisin on PHE precontracted endothelium-intact rat thoracic
Figure
aorta
rings.1.The vehicle control group was treated with distilled water. The relaxant effects of irisin on thoracic aorta
rings were calculated as a percentage of the contraction in response to 10 µM PHE. The data were expressed as the
mean ± SD. (n = 8). *: p < 0.05 vs. control. **: p < 0.001 vs. control.
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Figure 2. Effects of PKC inhibitor BIM I on irisin-induced relaxation in rat thoracic aorta. Relaxant effects of irisin on
Figure 2.
endothelium-intact
thoracic aorta rings were measured in the absence (control) or presence of BIM I. The relaxant
effects were calculated as a percentage of the contraction in response to 10 µM PHE. The data were expressed as the
mean ± SD. (n = 8). *: p < 0.05 vs. control. **: p < 0.001 vs. control.
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Figure 3. Effects of DMSO (at the solvent concentration of 50 µL) on irisin-induced relaxation in rat thoracic aorta.
Figureeffects
3. of irisin on endothelium-intact thoracic aorta rings were measured in the absence (control) or
Relaxant
presence of DMSO. The relaxant effects were calculated as a percentage of the contraction in response to 10 µM PHE.
The data were expressed as the mean ± SD (n = 8).

517

DEMİREL et al. / Turk J Med Sci
Table. Descriptive statistics for each group. Outliers have been corrected.
Test of Normality
Concentration
(log M)

VEHICLE
CONTROL
(n = 8)

IRISIN
(n = 8)

BIM-I
(n = 8)

DMSO
(n = 8)

Mean

Median

Shapiro-Wilk
Statistic

p

-9

0.50

0.00

0.00

0.724

0.004

-8

0.62

0.00

0.00

0.693

0.002

-7

0.87

0.50

0.01

0.809

0.036

-6

0.62

0.00

0.00

0.693

0.002

-9

2.12

1.50

2.66

0.945

0.662

-8

15.50

15.00

3.16

0.957

0.785

-7

29.00

29.50

4.62

0.943

0.644

-6

39.62

39.50

3.77

0.954

0.747

-9

0.00

0.50

1.71

0.929

0.503

-8

0.50

2.50

1.80

0.786

0.020

-7

0.00

0.50

2.06

0.911

0.361

-6

0.00

0.50

2.47

0.894

0.255

-9

1.62

2.00

1.08

0.875

0.168

-8

14.12

13.50

2.70

0.913

0.378

-7

29.75

30.00

2.85

0.952

0.727

-6

38.25

39.50

3.26

0.913

0.377

Despite great advances in medicine, proper treatment
of arterial hypertension, diabetes mellitus, and chronic
kidney disease remains a major challenge. Undiagnosed
and untreated arterial hypertension or diabetes mellitus
may lead to the development of chronic kidney disease
and, consequently, to cardiovascular disorders [8].
The frequency of insulin resistance, obesity, and type
II diabetes mellitus, and cardiovascular diseases such as
hypertension and atherosclerosis due to these diseases has
increased. Atherosclerosis, the main cause of coronary
artery disease and stroke, remains the primary cause of
global mortality [9,10].
Skeletal muscles have been defined as the endocrine
organ in recent years [11]. Cytokines known as myokines,
released from skeletal muscles during and/or immediately
after exercise, mediate the beneficial effects of exercise on
metabolism and the cardiovascular system [12,13].
Irisin, a newly described myokine, is increased
with exercise and has the potential to play a preventive
and/or therapeutic role in the management of the
aforementioned chronic diseases [1,14,15-20]. In this
context, it is considered that irisin may be an important
therapeutic target in the prevention of the development of
vascular pathologies and the treatment of atherosclerotic
cardiovascular diseases. The precise functions of irisin
related to the vascular tissue have not yet been clarified.
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However, few current studies have focused on the effects
of irisin on vascular activity and the mechanisms involved.
Zhang et al. [15] have found that central administration
of irisin increases blood pressure and cardiac contractility.
In contrast, peripheral administration of irisin reduces
blood pressure in both control and spontaneously
hypertensive rats. Irisin dilates mesenteric artery rings
through ATP-sensitive potassium channels. Han et
al. [16] have provided the first evidence that irisin
improves endothelial function in aortas of high-fat-dietinduced obese mice. The mechanism for this protective
effect is related to the activation of the 5’ adenosine
monophosphate-activated protein kinase (AMPK)endothelial nitric oxide synthase (eNOS) signaling
pathway. Jiang et al. [17] have investigated the effects of
irisin on vascular activity and the mechanisms involved
in mouse mesenteric arteries. They reported that irisin
induced both endothelium-dependent and -independent
relaxation in a dose-dependent manner. Endotheliumdependent relaxation is mediated by the nitric oxide (NO)cyclic guanosine monophosphate (cGMP) dependent
pathway, while endothelium-independent relaxation may
be influenced by reducing Ca2+ influx through inhibiting
voltage-dependent Ca2+ channels and intracellular Ca2+
release through both inositol-trisphosphate receptor
(IP3R) and ryanodine receptor (RyR) channels. Fu et al.
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[18] have concluded that acute administration of irisin
increases endothelium-dependent vasodilation and
lowers the blood pressure of spontaneously hypertensive
rats by amelioration of endothelial dysfunction of the
mesenteric artery through the AMPK-protein kinase B
(Akt)-eNOS-NO signaling pathway. Hou et al. [19] have
shown that irisin improves the anticontractile properties
of perivascular adipose tissue (PVAT) from the thoracic
aorta in diet-induced obese mice. The mechanism
for protective effects of irisin appears to be related to
upregulation of the heme oxygenase-1/adiponectin axis
in PVAT and browning of PVAT. Ye et al. [20] have stated
that irisin-induced endothelium-dependent vasodilation
is related to the stimulation of extracellular Ca2+ influx via
transient receptor potential vanilloid subtype 4 (TRPV4)
channels in rat mesenteric arteries.
PKC is a key regulatory enzyme involved in the
transduction of signals in several cellular functions in
vascular smooth muscle cells, including vascular smooth
muscle contractility [21]. PKC regulates the contractility
of vascular smooth muscle cells in various pathways,
including changes in myofilaments Ca2+-sensitivity and
regulation of intracellular free calcium concentration
([Ca2+]i, as well as by reducing endothelium-mediated
vasodilation [22-24]. This enzyme is also involved in
the regulation of the plasmalemma ion permeability in
vascular smooth muscle cells. For instance, PKC has
been shown to regulate the activity of K+ channels. PKC
can influence vascular activity by physiological changes
both in Ca2+ concentrations and membrane potential. The
increased reactivity of the vascular wall is also associated
with blunted endothelium-dependent responses due to
reduced sensitivity to NO. Briefly, increased vascular
smooth muscle cells myofilaments Ca2+ sensitivity and
decreased sensitivity to NO can both be the result of a
change in PKC activity [25]. The demonstration of a recent
study that irisin suppresses oxidative/nitrative stresses by
inhibiting PKC-β-related pathways in human umbilical
vein endothelial cells cultured in high-glucose/high-fat
[26] suggests that the vasodilator effect of irisin may also
be due to the inhibition of signaling pathways implicating
PKC. Although it is commonly accepted that PKC signaling
inhibits eNOS activity, the distinct role of different PKC
isoforms has not been studied so far. The PKC family
comprises roughly 12 different isozymes that activate
distinct downstream pathways. In this regard, activation
of PKCα leads to phosphorylation of calponin, an actinrelated regulatory protein in smooth muscle cells, resulting
in vascular smooth muscle contraction; on the other hand,
it can cause positive modulation of blood flow through the
activation of eNOS in the endothelium [27,28].
In the present study, we investigated the role of PKC
on the concentration-dependent relaxation responses of

irisin. The vasorelaxant effects of irisin were significantly
attenuated by pretreatment with PKC inhibitor BIM I,
suggesting that signaling pathways implicating PKC may
be associated with irisin-induced vasodilation. Thus, our
results demonstrate for the first time that PKC stimulates
irisin-induced vasodilation in rat thoracic aorta. However,
PKC isoforms may have opposite effects on irisin-induced
vasodilation. Therefore, further study is necessary to
examine the hypothesis that irisin induces relaxation by
enhancing the PKC-mediated nitric oxide synthesis in
endothelium and/or inhibiting the PKC-regulated Ca
sensitivity in vascular smooth muscle. Besides, further
research using specific activators and inhibitors is required
to clarify this effect.
Differences could be observed in the vasodilator
activity of irisin on different vascular preparations obtained
from various species. It is thought that this may be due to
methodological differences such as the species from which
the tissues were removed, the vascular tissues in which
the experiments were performed (locations and diameters
of vascular tissues), and/or the agents used to induce
precontraction. Vasoreactivities of the arteries may be
different from each other. It is known that the density and
types of ion transport mechanisms and/or physiological/
pharmacological receptors, as well as differences in
substances released from the endothelium, could have
an important role in changes in the responses of vascular
smooth muscles to various agents [29,30]. For instance,
the effects of hyperpolarizing factors increase inversely
with vessel diameter [31]. Therefore, in the present study,
the relaxing effects of irisin were investigated in thoracic
aorta preparations isolated from Wistar Albino rats.
Furthermore, the possible role of PKC regarding action
mechanisms of irisin assessed in this study has not been
performed on any species and/or vascular tissues before.
In this context, our results showed that 0.01, 0.1, and 1
µM concentrations of irisin have a vasodilatative effect on
rat thoracic aorta, a conducting artery. Thus, we reported
that irisin has relaxing effects on vascular smooth muscle
contractility both at mean plasma concentration (0.1
µM) [18] and a wide range of concentrations, including
the upper and lower levels of mean concentration (0.011 µM). Pretreatment with DMSO, a solvent of BIM I, did
not modulate irisin-induced relaxation. It was further
demonstrated that the irisin-induced vasorelaxation effects
on endothelium-intact rat thoracic aorta were significantly
abolished by pretreatment with PKC inhibitor BIM I. Thus,
this study provides the first evidence that irisin-induced
vasodilation is regulated probably via activating signaling
pathways implicating PKC.
In conclusion, this study demonstrated that irisin
induces concentration-dependent relaxation responses in
endothelium-intact rat thoracic aorta rings. Furthermore,
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the present study is the first to report that the mechanism
for this vasorelaxant effect is associated with the activity
of PKC. These results suggest that irisin might be a useful
agent in the treatment of abnormal vasoconstrictionrelated diseases such as hypertension and atherosclerosis,
in addition to its key role in regulating energy metabolism,
resulting in thermogenesis and weight loss, by increasing
uncoupling protein-1 (UCP-1) expression in adipose
tissue. This study further supports the beneficial effect of
exercise on vascular function, depending on the release of
irisin, an exercise hormone.
However, the findings presented in our study are
preliminary. The precise roles of signaling pathways
implicating PKC in irisin-mediated vasodilation need to
be further elucidated in clinically relevant animal models.

Besides, more detailed mechanism studies and in vivo
studies are necessary to establish the efficacy of irisin in
the management and treatment of cardiovascular diseases.
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